



APPLICATION OF MEDICAL CANNABIS IN PATIENTS WITH THE NEURODEGENERATION DISORDERS

LIDIA KOTUŁA, PAULINA SOBSTYL, JAN SOBSTYL, PAULINA CHWIL, KAROL TERLECKI, JOLANTA KARWAT, PAULINA GIL-KULIK, ALICJA NIEDOJADŁO, JANUSZ KOCKI

Key words: *Cannabis sativa*, medical cannabis, neurodegeneration, immunomodulator, cannabinoid receptors

Department of Clinical Genetics, Medical University of Lublin, Radziwiłłowska str. 11, 20-080 Lublin, Poland

Medical cannabis is the dried flowers of the female *Cannabis sativa* L. plant. Cannabis contains a number of active elements, including dronabinol (THC) and cannabidiol (CBD). Dronabinol is usually the main ingredient. The body's own cannabinoid system has been identified. The discovery of this system, which comprises endocannabinoids and receptors, confirmed that cannabis has a positive effect on certain illnesses and conditions. Two types of cannabinoid receptors have been identified: CB1 and CB2 receptors. The first type CB1 is

mostly found in the central nervous system, modulate pain. It also has an anti-emetic effect, and has influence on the memory and the motor system. The second type of receptors CB2 is peripheral, and it is primarily found in immune system cells and it is responsible for the immunomodulatory effects of cannabinoids.

Medical cannabis can help in cases of the neurodegeneration disorders, for example Parkinson's disease, Huntington's Disease, Amyotrophic Lateral Sclerosis. Patients generally tolerate medical cannabis well.